Status:

COMPLETED

Relative Bioavailability of Meloxicam 2 x 7.5 mg Tablets Compared to 15 mg Tablet and Dose Proportionality Over a Dose Range of 7.5 mg and 15 mg in Healthy Volunteers

Lead Sponsor:

Boehringer Ingelheim

Conditions:

Healthy

Eligibility:

All Genders

18-50 years

Phase:

PHASE1

Brief Summary

Study to assess the relative bioavailability of two 7.5 mg meloxicam tablets (American type) compared to one 15 mg meloxicam tablet (American type), and to investigate dose-proportionality over the do...

Eligibility Criteria

Inclusion

  • Healthy subjects as determined by results of screening
  • Written informed consent in accordance with Good Clinical Practice (GCP) and local legislation
  • Age \>= 18 and \<= 50 years
  • Broca \>= -20% and \<= + 20 %

Exclusion

  • Any finding of the medical examination (including laboratory blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Surgery of the gastro-intestinal tract (except appendectomy)
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders
  • Chronic or relevant acute infections
  • Hypersensitivity to meloxicam and/or non-steroidal antirheumatic agents
  • Intake of drugs with a long half-life (\>24 hours) (\<= 1 month prior to administration or during the trial)
  • Use of any drugs which might influence the results of the trial (\<= 10 days prior to administration or during the trial)
  • Participation in another trial with an investigational drug (\<= 2 months prior to administration or during the trial)
  • Smoker (\>= 10 cigarettes or \>= 3 cigars or \>= 3 pipes/day)
  • Inability to refrain from smoking on study days
  • Alcohol abuse
  • Drug abuse
  • Blood donation (\<= 1 months prior to administration)
  • Excessive physical activities (\<= 5 days prior to administration)
  • History of hemorrhagic diatheses
  • History of gastro-intestinal ulcer, perforation or bleeding
  • History of bronchial asthma
  • For female subjects:
  • Pregnancy
  • Positive pregnancy test
  • No adequate contraception e.g. sterilization, intrauterine device (IUD), oral contraceptives
  • Inability to maintain this adequate contraception during the whole study period
  • Lactating

Key Trial Info

Start Date :

June 1 1999

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

Estimated Enrollment :

18 Patients enrolled

Trial Details

Trial ID

NCT02276352

Start Date

June 1 1999

Last Update

October 28 2014

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.